keyword
https://read.qxmd.com/read/38633948/navigating-treatment-dilemmas-recalcitrant-pemphigus-and-the-burden-of-multiple-comorbidities
#1
Priya Garg, Kshitiz Lakhey, Nishtha Mishra, Yash Buccha, Kirti S Deo
Pemphigus vulgaris is a chronic autoimmune disease of the skin caused by the production of autoantibodies targeting desmogleins 1 and 3 usually presenting in individuals with an average age of onset of approximately 40 years. A 35-year-old obese, diabetic woman presented with fluid-filled lesions over her body for three months along with erosions and painful ulcers in her mouth and genital area for two months. Based on clinical and histopathological studies, the patient was diagnosed as a case of pemphigus vulgaris...
March 2024: Curēus
https://read.qxmd.com/read/38632123/anti-cfh-associated-hemolytic-uremic-syndrome-do-we-still-need-plasma-exchange
#2
JOURNAL ARTICLE
Marion Ferri, Federica Zotta, Roberta Donadelli, Claire Dossier, Charlotte Duneton, Carine El-Sissy, Véronique Fremeau-Bacchi, Thérésa Kwon, Lisa Quadri, Andrea Pasini, Anne-Laure Sellier-Leclerc, Marina Vivarelli, Julien Hogan
BACKGROUND: Between 5 and 50% of atypical hemolytic uremic syndrome (aHUS) cases in children are caused by autoantibodies against complement factor H (CFH). Given the acquired autoimmune nature of the disease, plasma exchange (PE) and various immunosuppressive treatments have been used. More recently, eculizumab has been proposed. METHODS: In this multicenter, retrospective study, we report outcomes of 12 children with anti-FH antibody-associated HUS treated with eculizumab associated with various immunosuppressive regimens...
April 17, 2024: Pediatric Nephrology
https://read.qxmd.com/read/38623524/effective-treatment-of-steroid-resistant-immune-checkpoint-inhibitor-pneumonitis-with-mycophenolate-mofetil
#3
Nao Shioiri, Ryota Kikuchi, Itsuka Matsumoto, Kanako Furukawa, Kenichi Kobayashi, Shinji Abe
Insufficient evidence is available for treating steroid-resistant immune checkpoint inhibitor pneumonitis (CIP). Although guidelines recommend the use of immunosuppressants, the efficacy of mycophenolate mofetil (MMF) has not been sufficiently verified. We report two cases of steroid-resistant CIP treated with MMF. Both patients responded to initial treatment with prednisolone (PSL), but the CIP flared up repeatedly as the steroids were gradually tapered off. Upon receiving MMF in addition to PSL, their subjective symptoms improved, and the shadows gradually disappeared, allowing for a reduction in the steroid dose...
April 2024: Respirology Case Reports
https://read.qxmd.com/read/38621245/pulmonology-what-you-may-have-missed-in-2023
#4
JOURNAL ARTICLE
Aram Karkar, Sana Khan, Rebecca O'Leary, Albina Tyker, Michael Unger
The field of pulmonology saw significant advances in 2023. The publications highlighted in this article address advances and changes in practice related to asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, pleural disorders, and sleep-disordered breathing. One article reviews data examining the efficacy of vaccination against respiratory syncytial virus, a respiratory viral illness that has had devastating effects globally. Four studies evaluate the role of various therapies in COPD, including dupilumab, ensifentrine, pulmonary rehabilitation programs, and lung volume reduction versus endobronchial valves...
April 16, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38615143/post-transplant-cyclophosphamide-calcineurin-inhibitor-and-mycophenolate-mofetil-compared-to-anti-thymocyte-globulin-calcineurin-inhibitor-and-methotrexate-combinations-as-graft-versus-host-disease-prophylaxis-post-allogeneic-stem-cell-transplantation-from
#5
JOURNAL ARTICLE
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Thomas Schroeder, Rose-Marie Hamladji, Laimonas Griskevicius, Urpu Salmenniemi, Alessandro Rambaldi, Stephan Mielke, Alexander Kulagin, Jakob Passweg, Thomas Luft, Tobias Gedde-Dahl, Edouard Forcade, Grzegorz Helbig, Matthias Stelljes, Cristina Castilla-Llorente, Alexandros Spyridonidis, Eolia Brissot, Fabio Ciceri, Mohamad Mohty
Post-transplant cyclophosphamide plus calcineurin inhibitor (CNI)(tacrolimus or cyclosporine A) plus mycophenolate mofetil (PTCy/TAC or CSA/MMF) and anti-thymocyte globulin plus CNI (tacrolimus or cyclosporine A) plus methotrexate (ATG/TAC or CSA/MTX) are common graft-versus-host disease (GVHD) prophylaxis regimens. We compared the two regimens in patients with acute myeloid leukemia (AML) undergoing allogeneic transplantation from matched siblings or unrelated donors. 402 received PTCy/TAC or CSA/MMF and 5648 received ATG/TAC or CSA/MTX...
April 13, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38607424/do-we-really-need-cyclophosphamide-for-lupus-nephritis
#6
JOURNAL ARTICLE
Scott E Wenderfer, Jennifer C Cooper
A 14-year-old patient presents with hematuria and proteinuria. Clinical evaluation reveals a positive anti-nuclear antibody titer, positive anti-double stranded DNA antibody and hypocomplementemia. Systemic lupus erythematosus (SLE) is diagnosed based on the 2019 EULAR/ACR (European League Against Rheumatism/American College of Rheumatology) classification criteria (Aringer et al. Arthritis Rheumatol 71:1400-1412, 2019). A kidney biopsy is performed that confirms the presence of immune complex glomerulonephritis, ISN-RPS (International Society of Nephrology/Renal Pathology Society) class IV (Bajema et al...
April 12, 2024: Pediatric Nephrology
https://read.qxmd.com/read/38603944/acute-rejection-rates-in-vascularized-composite-allografts-a-systematic-review-of-case-reports
#7
REVIEW
Loïc Van Dieren, Pierre Tawa, Marie Coppens, Laura Naenen, Omer Dogan, Tom Quisenaerts, Hyshem H Lancia, Haïzam Oubari, Yohann Dabi, Maxime De Fré, Filip Thiessen Ef, Curtis L Cetrulo, Alexandre G Lellouch
INTRODUCTION: Vascularized Composite Allografts (VCA) are usually performed in a full major histocompatibility complex mismatch setting, with a risk of acute rejection depending on factors such as the type of immunosuppression therapy and the quality of graft preservation. In this systematic review, we present the different immunosuppression protocols used in VCA and point out relationships between acute rejection rates and possible factors that might influence it. METHODS: This systematic review was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines...
April 10, 2024: Journal of Surgical Research
https://read.qxmd.com/read/38602169/haploidentical-hematopoietic-stem-cell-transplantation-with-busulfan-cyclophosphamide-and-fludarabine-conditioning-for-x-linked-adrenal-cerebral-leukodystrophy
#8
JOURNAL ARTICLE
Yao Chen, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Kai-Yan Liu, Jiong Qing, Yan-Ling Yang, Xiao-Jun Huang
OBJECTIVE: We investigated the safety and efficacy of haploidentical stem cell transplantation (SCT) in pediatric patients with X-linked adrenoleukodystrophy (ALD). METHODS: A retrospective analysis of transplantation data from 29 cases of ALD, treated between December 2014 and April 2022, was conducted. Neurologic function scores (NFS) were assessed. The conditioning regimen was busulfan 9.6 mg/kg, cyclophosphamide 200 mg/kg, and fludarabine 90 mg/m2 (BFC)...
May 2024: Pediatric Transplantation
https://read.qxmd.com/read/38597437/-jianpi-zishen-granule-inhibits-podocyte-autophagy-in-systemic-lupus-erythematosus-a-network-pharmacology-and-clinical-study
#9
JOURNAL ARTICLE
J Chen, C Huang, M Li
OBJECTIVE: To explore the therapeutic mechanism of Jianpi Zishen (JPZS) granules for systemic lupus erythematosus(SLE) in light of podocyte autophagy regulation. METHODS: TCMSP, GeneCards, OMIM, and TTD databases were used to obtain the targets of JPZS granules, SLE, and podocyte autophagy. The protein-protein interaction network was constructed using Cytoscape, and the key active ingredients and targets were screened for molecular docking. In the clinical study, 46 patients with SLE were randomized into two groups to receive baseline treatment with prednisone acetate and mycophenolate mofetil (control group) and additional treatment with JPZS granules (observation group) for 12 weeks, with 10 healthy volunteers as the healthy control group...
March 20, 2024: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://read.qxmd.com/read/38594605/maternal-and-fetal-outcomes-in-pregnancy-complicated-by-pre-existing-lupus-nephritis-insights-from-a-developing-country-pakistan
#10
JOURNAL ARTICLE
Tabassum Elahi, Saima Ahmed, Muhammed Mubarak, Ejaz Ahmed
BACKGROUND: Pregnancy in women with systemic lupus erythematosus (SLE) has remained a great challenge for clinicians in terms of maternal and fetal outcomes. The outcomes in women with pre-existing lupus nephritis (LN) are variable. The impact of different classes of LN on maternal and fetal outcomes during pregnancy is not well defined, as data is very scarce, especially from the developing countries. METHODS: A retrospective analysis was conducted on 52 women with 89 pregnancies...
April 9, 2024: Lupus
https://read.qxmd.com/read/38589827/assessing-antiviral-treatment-efficacy-and-risk-factors-for-severe-covid-19-in-kidney-transplant-recipients-during-the-omicron-subvariant-dominant-period-a-retrospective-study
#11
JOURNAL ARTICLE
Takashi Sakaguchi, Akihiko Mitsuke, Yoichi Osako, Yasutoshi Yamada, Himawari Takeyama, Risako Ogawa, Katsuya Takahashi, Yukiko Hirohata, Sayuri Yamamoto, Junya Arima, Wataru Fukumoto, Satoshi Sugita, Satoru Inoguchi, Ryosuke Matsushita, Hirofumi Yoshino, Shuichi Tatarano, Hideki Enokida
BACKGROUND: Kidney transplant recipients (KTRs) are at risk of severe coronavirus disease 2019 (COVID-19), and even now that Omicron subvariants have become dominant, cases of severe disease are certain to occur. The aims of this retrospective study were to evaluate the efficacy of antiviral treatment for COVID-19 and to identify risk factors for severe disease in KTRs during Omicron subvariant-dominant periods. METHODS: A total of 65 KTRs diagnosed with COVID-19 who received antiviral treatment between July 2022 and September 2023 were analyzed...
April 8, 2024: BMC Nephrology
https://read.qxmd.com/read/38587826/systemic-lupus-erythematosus-a-review
#12
JOURNAL ARTICLE
Caroline H Siegel, Lisa R Sammaritano
IMPORTANCE: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and immune-mediated injury to multiple organ systems, including the mucocutaneous, musculoskeletal, hematologic, and kidney systems. Approximately 3.4 million people worldwide have received a diagnosis of SLE. OBSERVATIONS: Approximately 90% of people with SLE are female. Although there are no uniformly accepted diagnostic criteria for SLE, the 2019 European Alliance of Associations for Rheumatology (formerly the European League Against Rheumatism)/American College of Rheumatology classification criteria developed for scientific study are an estimated 96...
April 8, 2024: JAMA
https://read.qxmd.com/read/38587559/idiopathic-nephrotic-syndrome-in-syrian-children-clinicopathological-spectrum-treatment-and-outcomes
#13
JOURNAL ARTICLE
Hala Wannous
BACKGROUND: Idiopathic nephrotic syndrome (INS) is the most common glomerular disease in children. We performed this study to report histopathological findings, the correlation between clinical and histopathological features, and the response to steroids and other immunosuppressive drugs and outcomes in Syrian children with INS. METHODS: A single-center retrospective observational cohort study was conducted at Children's University Hospital in Damascus, and included all patients aged 1-14 years, admitted from January 2013 to December 2022, with INS and who underwent kidney biopsy...
April 8, 2024: Pediatric Nephrology
https://read.qxmd.com/read/38587355/enrolment-of-the-first-paediatric-cohort-into-the-australian-lupus-registry-and-biobank-a-single-centre-experience
#14
JOURNAL ARTICLE
Bronwyn D Power, Rangi Kandane-Rathnayake, Georgina Tiller, William D Renton, Angela Cox, Lilian Johnstone, Alberta Hoi, Peter Gowdie
INTRODUCTION: We aim to report on the feasibility of establishment of the first paediatric cohort as part of the longitudinal database of the Australian Lupus Registry and Biobank (ALRB) and to describe the enrolment data with a focus on clinical characteristics, serological data, treatment strategies and patient/parent-reported outcome measures. METHODS: All patients under the age of 18 years with a diagnosis of systemic lupus erythematosus (SLE) attending the paediatric rheumatology service of a single, tertiary hospital were identified...
April 8, 2024: Lupus
https://read.qxmd.com/read/38579324/therapeutic-management-of-fibrosis-in-systemic-sclerosis-patients-an-analysis-from-the-swiss-eustar-cohort
#15
JOURNAL ARTICLE
Kevin Windirsch, Suzana Jordan, Mike Oliver Becker, Cosimo Bruni, Rucsandra Dobrota, Muriel Elhai, Ion-Alexandru Garaiman, Carmen-Marina Mihai, Michele Iudici, Paul Hasler, Camillo Ribi, Britta Maurer, Armando Gabrielli, Anna-Maria Hoffmann-Vold, Oliver Distler
OBJECTIVES: Systemic sclerosis is a chronic autoimmune connective tissue disease leading to microvascular and fibrotic manifestations in multiple organs. Several treatment options and recommendations from different European countries are available. In this study, for which the ambit is Switzerland specifically, we aim to describe the treatment patterns of systemic sclerosis patients with fibrotic manifestations. METHODS: Systemic sclerosis patients were selected from six Swiss tertiary centres recorded in the multicentre, prospective European Scleroderma Trials and Research (EUSTAR) registry...
February 6, 2024: Swiss Medical Weekly
https://read.qxmd.com/read/38579022/clinicopathological-correlation-of-patients-with-lupus-nephritis-data-from-a-tertiary-center-in-saudi-arabia
#16
JOURNAL ARTICLE
Yasser Bawazir
Systemic lupus erythematosus mainly affects young women, and approximately half of systemic lupus erythematosus patients develop lupus nephritis (LN). However, data on the types and remission rates of LN in Saudi Arabia are limited. Therefore, we aimed to highlight the LN remission rates in our population. A retrospective record review was conducted between January 2007 and December 2020 in a tertiary center in the western region of Saudi Arabia to determine the remission rates among patients with biopsy-proven LN who met the EULAR\ACR 2019 classification criteria...
April 5, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38576821/immunoglobulin-a-glomerulonephropathy-a-review
#17
EDITORIAL
Mohamad El Labban, Salim Surani
In this editorial, we comment on the article by Meng et al published in the World Journal of Clinical Cases. We comprehensively review immunoglobulin A nephropathy (IgAN), including epidemiology, clinical presentation, diagnosis, and management. IgAN, also known as Berger's disease, is the most frequent type of primary glomerulonephritis (GN) globally. It is mostly found among the Asian population. The presentation can be variable, from microscopic hematuria to a rapidly progressive GN. Around 50% of patients present with single or recurring episodes of gross hematuria...
March 16, 2024: World Journal of Clinical Cases
https://read.qxmd.com/read/38576749/update-on-the-reciprocal-interference-between-immunosuppressive-therapy-and-gut-microbiota-after-kidney-transplantation
#18
REVIEW
Maurizio Salvadori, Giuseppina Rosso
Gut microbiota is often modified after kidney transplantation. This principally happens in the first period after transplantation. Antibiotics and, most of all, immunosuppressive drugs are the main responsible. The relationship between immunosuppressive drugs and the gut microbiota is bilateral. From one side immunosuppressive drugs modify the gut microbiota, often generating dysbiosis; from the other side microbiota may interfere with the immunosuppressant pharmacokinetics, producing products more or less active with respect to the original drug...
March 18, 2024: World Journal of Transplantation
https://read.qxmd.com/read/38576149/zilucoplan-zilbrysq-for-myasthenia-gravis
#19
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 15, 2024: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38570792/effectiveness-and-safety-of-mycophenolate-mofetil-and-rituximab-combination-therapy-for-immune-idiopathic-myopathies
#20
JOURNAL ARTICLE
Corrado Campochiaro, Nicola Farina, Giacomo De Luca, Veronica Batani, Giorgia Trignani, Davide Vignale, Anna Palmisano, Marco Matucci-Cerinic, Lorenzo Dagna
INTRODUCTION: Idiopathic inflammatory myopathies (IIM) represent a rare and heterogenous group diseases, and their treatment is not fully defined yet. According to previous small case series, the combination of mycophenolate mofetil (MMF) and rituximab (RTX) may be effective in controlling difficult-to-treat patients. Our aim was to further explore the efficacy and safety of this combined approach in patients with IIM. METHODS: Patients with IIM treated with the RTX/MMF combination in our Center were retrospectively identified...
April 3, 2024: Arthritis Research & Therapy
keyword
keyword
51015
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.